Gar Yang Chau
Taipei Veterans General Hospital
4 Papers
5 Citations
Gar Yang Chau is an academic researcher from Taipei Veterans General Hospital. The author has contributed to research in topics: Sorafenib & Adjuvant therapy. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie Tung-Ping Poon,Kwang Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie Aude Le Berre,Gerold Meinhardt,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: The data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
983
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni,Josep M. Llovet,Guohong Han,Won Young Tak,Jiamei Yang,Alfredo Guglielmi,Seung Woon Paik,Maria Reig,Do Young Kim,Gar Yang Chau,Angelo Luca,Luis Ruiz del Arbol,Marie Aude Leberre,Woody Niu,Kate Nicholson,Gerold Meinhardt,Jordi Bruix +16 more
TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.
646
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Roser Pinyol,Robert Montal,Laia Bassaganyas,Daniela Sia,Tadatoshi Takayama,Gar Yang Chau,Vincenzo Mazzaferro,Sasan Roayaie,Han Chu Lee,Norihiro Kokudo,Zhongyang Zhang,Sara Torrecilla,Agrin Moeini,Leonardo Rodriguez-Carunchio,Edward Gane,Chris Verslype,Adina Emilia Croitoru,Umberto Cillo,Manuel De La Mata,Luigi Lupo,Simone I. Strasser,Joong-Won Park,Jordi Camps,Manel Solé,Swan N. Thung,Augusto Villanueva,Carol Peña,Gerold Meinhardt,Jordi Bruix,Josep M. Llovet +29 more
TL;DR: BIOSTORM recapitulates clinicopathological characteristics of STORM and defines predictors of recurrence prevention with sorafenib and prognostic factors with B level of evidence, finding only hepatocytic pERK and microvascular invasion predicted poor RFS.
Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
Roser Pinyol,Robert Montal,Tadatoshi Takayama,Gar Yang Chau,Vincenzo Mazzaferro,Sasan Roayaie,Han Chu Lee,Ronnie T.P. Poon,Norihiro Kokudo,Zhongyang Zhang,Laia Bassaganyas,Sara Torrecilla,Agrin Moeini,Leonardo Rodriguez-Carunchio,E.J. Gane,Chris Verslype,A.E. Croitoru,U. Cillo,M. de la Mata,Luigi Lupo,Simone I. Strasser,Joong-Won Park,Jordi Camps,Manel Solé,S. Thung,A. Villanueva,Carol Peña,G. Meinhart,Jordi Bruix,Josep M. Llovet +29 more
5